23 February 2024
Unlocking AI Excellence: BI4ALL’s Commitment to Pharma & Healthcare
Unlocking AI Excellence: BI4ALL’s Commitment to Pharma & Healthcare
Switzerland, 26th. September 2023 – Due to the ever-increasing proliferation of technological innovations in the pharmaceutical industry, the proper use of Data Analytics and Artificial Intelligence (AI) solutions is also playing an increasingly important role. Data Analytics and Artificial intelligence are driving significant change across healthcare and offer unprecedented potential to improve outcomes for patients and healthcare professionals, with the ability to analyse vast amounts of patient data, identify patterns and trends, and help with diagnosis while providing personalised treatment recommendations. To harness all this new information and insight, Data Analytics and AI solutions promise to shape the sector´s future by bringing optimization, efficiency and agility.
AI as a support for the development of medicines
Drug development is an expensive and time-consuming process, and this is a problem for the pharmaceutical industry. Traditional drug discovery often takes years and billions of dollars to market new, effective, safe drugs. AI has the potential to revolutionise this process, from the generation of novel molecules to ensuring timely, cost-effective trials. AI can be useful in the following four phases:
- Generative AI can be used on very large datasets to train models and generate new – and optimised – molecules to target the right protein. Key techniques, such as Generative Adversarial Networks, Variational Autoencoders or Reinforced Learning, are used to 1) generate molecular structures with the designed properties, 2) optimise molecular efficacy and safety, and 3) predict biological activity, thus reducing the need for extensive experimental testing.
- Acceleration of clinical trials: In clinical trials, the selection of suitable candidates (and their follow-up through the whole program)can influence the duration and success of the program. AI can help identify patterns to distinguish good candidates and control their attrition during several phases, ensuring the proper distribution and follow-through of the groups of trial participants.
A new COVID-19 treatment- an AI-designed oral drug- has recently moved to Phase I clinical trials. Generative AI was used to generate new molecules that would attach a target protein within the coronavirus, with ISM3312 proving to be the “hit molecule” with effective results.
Source: https://www.clinicaltrialsarena.com/news/insilico-medicine-trials-covid-19/?cf-view
AI applied to emotional data
Properly applied, AI is exceptionally good at identifying patterns and behaviours. Using a model developed by BI4ALL, it was possible to identify the emotionality of reviews and comments on social media about a customer’s specific products, as well as trends in the expressions used in the comments. This, in turn, led to the customer being able to respond proactively at an early stage. For example, thanks to the available data and its targeted evaluation, a customer discovered a possible new allergy and was able to counteract it at an early stage.
AI supports the omnichannel overview
For the pharmaceutical industry, it is relevant to know how and when to address health personnel and hospitals to inform them about developments in research and new products. During the Corona pandemic, it was not so easy to reach the contact persons promptly and efficiently. For this reason, a so-called omnichannel overview was created for a customer. Based on this AI-based overview, the customer received personalised recommendations on when and how to optimally contact the target persons by indicating preferred contact timings and methods and pointing out the next best action. This, in turn, improved customer loyalty and increased sales-force effectiveness.
“AI solutions are becoming critical in the transformation of the value chain in the healthcare industry, from the acceleration of drug research and optimisation of clinical trials to the enhancement of the relationship with the patient in the treatment and post-treatment phase. More than ever, healthcare companies, professionals and patients have AI as their greatest companion, extending the reach of the formers (and contributing to focusing the scarce human resources in the right value paths) and improving the quality of life of the latter (through personalised treatments and specialised tracking companions). More than a trend, AI is an inevitability in healthcare..”, André Santana, Business Development Lead at BI4ALL.
“For 19 years, we have been working with companies in the pharmaceutical and healthcare sector to offer them the most innovative technologies and the best tools on the market. Data Analytics and AI solutions have a significant impact on organisations in the sector; from the development of personalised medicines to the optimisation of clinical trials, there is a wide world of opportunities that guarantee efficiency, precision and transparency.” José Oliveira, CEO and Chairman, BI4ALL
